YL Biologics (YLB) has announced that a Phase III clinical trial of its investigational Enbrel (etanercept) biosimilar YLB113 has met its primary endpoint.
YLB is a joint venture formed in 2014 by Indian pharma major Lupin and Japan’s Yoshindo to develop biosimilars, starting with YLB113.
The yearlong study demonstrated that the firms’ copycat candidate scored an equivalent improvement in rheumatoid arthritis, as measured by American College of Rheumatology 20 (ACR20) response rate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze